Literature DB >> 19897959

Therapeutic options to modulate barrier defects in inflammatory bowel disease.

Nina A Hering1, Jörg-Dieter Schulzke.   

Abstract

In inflammatory bowel disease (IBD), epithelial barrier function is impaired contributing to diarrhea by a leak flux mechanism and perpetuating inflammation by an increased luminal antigen uptake. This barrier of the intestinal epithelium is composed of the apical enterocyte membrane and the epithelial tight junction (TJ) and can be affected by TJ alterations, induction of epithelial apoptosis and appearance of gross lesions like erosions or ulcers as well as by accelerated transcytotic antigen uptake. TJ strands are reduced in Crohn's disease (CD) and strand breaks appear. Several of the 24 claudins are concerned in CD as e.g. claudin-2, -5 and -8. The epithelial apoptotic rate has also been shown to be elevated causing focal lesions. As far as regulation is concerned, Th1 cytokines like TNF-alpha and interferon-gamma are important for CD, while Th2 responses are dominated by interleukin (IL)-13 and TNF-alpha in ulcerative colitis (UC). IL-13 does stimulate epithelial apoptosis as well as upregulates claudin-2 in UC. Together with an IL-13-dependent restitution arrest, this may explain why ulcer lesions are seen already early in UC but only in advanced stages of CD. Luminal antigen uptake occurs via TJ discontinuities, epithelial gross lesions and endocytotically. Therapeutically, anti-inflammatory remedies as e.g. TNF-alpha antibodies are most effective in improving active IBD and in parallel repairing barrier function. Again, this is assumed to be due to reduced cytokine release in active IBD, as a result of immune cell apoptosis. However, other agents can also directly affect barrier function. Glutamine is discussed as a candidate for barrier therapy but has never been shown to have a direct barrier influence in CD, although it is an important metabolic fuel for enterocytes and has been shown to preserve barrier functions in laboratory models. Also, probiotics and TGF-beta and have beneficial effects in models, but no data exist on barrier repair in IBD. In contrast, zinc has been shown to improve barrier function in CD, although the inherent mechanisms are unknown. Finally, food components can strengthen the epithelial barrier as for example the flavonoid quercetin which has been shown to upregulate claudin-4 within the epithelial TJ.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897959     DOI: 10.1159/000233283

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  37 in total

1.  Zinc proteome interaction network as a model to identify nutrient-affected pathways in human pathologies.

Authors:  Guido Leoni; Antonio Rosato; Giuditta Perozzi; Chiara Murgia
Journal:  Genes Nutr       Date:  2014-11-04       Impact factor: 5.523

2.  Moxibustion inhibits apoptosis and tumor necrosis factor-alpha/tumor necrosis factor receptor 1 in the colonic epithelium of Crohn's disease model rats.

Authors:  Chun-Hui Bao; Lu-Yi Wu; Huan-Gan Wu; Yin Shi; Hui-Rong Liu; Rong Zhang; Li-Qing Yu; Jin-Hai Wang
Journal:  Dig Dis Sci       Date:  2012-04-25       Impact factor: 3.199

Review 3.  New molecular insights into inflammatory bowel disease-induced diarrhea.

Authors:  Yueming Tang; Christopher B Forsyth; Ali Keshavarzian
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-10       Impact factor: 3.869

Review 4.  Maintenance of Intestinal Epithelial Homeostasis by Zinc Transporters.

Authors:  Wakana Ohashi; Takafumi Hara; Teruhisa Takagishi; Koji Hase; Toshiyuki Fukada
Journal:  Dig Dis Sci       Date:  2019-03-04       Impact factor: 3.199

5.  Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier function.

Authors:  Tiha M Long; Shahista Nisa; Michael S Donnenberg; Bret A Hassel
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

Review 6.  Zinc and gastrointestinal disease.

Authors:  Sonja Skrovanek; Katherine DiGuilio; Robert Bailey; William Huntington; Ryan Urbas; Barani Mayilvaganan; Giancarlo Mercogliano; James M Mullin
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

7.  VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis.

Authors:  Cong Dai; Chang-Qing Zheng; Fan-Ji Meng; Zheng Zhou; Li-Xuan Sang; Min Jiang
Journal:  Mol Cell Biochem       Date:  2012-10-23       Impact factor: 3.396

Review 8.  Active and passive involvement of claudins in the pathophysiology of intestinal inflammatory diseases.

Authors:  Christian Barmeyer; Michael Fromm; Jörg-Dieter Schulzke
Journal:  Pflugers Arch       Date:  2016-11-30       Impact factor: 3.657

9.  Effects of alanyl-glutamine dipeptide on the expression of colon-inflammatory mediators during the recovery phase of colitis induced by dextran sulfate sodium.

Authors:  Yu-Chen Hou; Chia-Chou Chu; Tsui-Ling Ko; Chiu-Li Yeh; Sung-Ling Yeh
Journal:  Eur J Nutr       Date:  2012-07-31       Impact factor: 5.614

10.  Contribution of gut bacteria to liver pathobiology.

Authors:  Gakuhei Son; Michael Kremer; Ian N Hines
Journal:  Gastroenterol Res Pract       Date:  2010-07-28       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.